With deep roots in endocrinology research, our scientists have designed a pipeline of investigational new drug candidates to treat patients with rare endocrine diseases or tumors, including acromegaly, neuroendocrine tumors, Cushing’s disease, congenital adrenal hyperplasia, and congenital hyperinsulinism. We continue to work hard to find additional drug candidates for patients with other rare endocrine diseases and tumors.

Our lead product candidate, Paltusotine, is a new oral non-peptide designed for the treatment of acromegaly. A half-life of 42 to 50 hours supports once daily administration. Like other traditional oral small molecules, Paltusotine is intrinsically gut permeable. It is thought to act on the somatostatin type 2 receptors in pituitary tumors to reduce the excess secretion of growth hormone, which in turn reduces the release of insulin-like growth factor 1 by the liver.

If proven effective, Paltusotine may allow the patient to manage their disease with a tablet taken only once a day, without the need for monthly injections of long-acting somatostatin analogs. Paltusotine has been evaluated in healthy volunteers and is now in acromegaly patient clinical trials.

Also in development are potential new treatments for neuroendocrine tumors, Cushing’s disease, congenital adrenal hyperplasia, and congenital hyperinsulinism. Crinetics is the endocrine company dedicated to creating innovative therapeutics for patients eager to manage their disease with new solutions. For more information, contact Crinetics Pharmaceuticals.